Joyce O'Shaughnessy, an investigator in the trial, stressed that while the study doesn't have the statistical power to conclude ductal lavage is a useful screening tool for detecting breast cancer, it does establish the technique as a helpful means of further stratifying an individual's risk beyond Gail score alone.
O'Shaughnessy said "there is a huge amount of interest" in ductal lavage among breast cancer specialists around the country An example of the sort of highly practical question she would love to see answered through a clinical trial or registry data is this: If a woman at high lifetime risk of breast cancer based upon a high Gail score has benign findings on lavage and her lavage remains benign a year later, does she need to take tamoxifen?
Joyce O'Shaughnessy, an investigator in the trial, stressed that while the study lacked the statistical power to show that ductal lavage is a useful screening tool, it does establish the technique as a helpful means of further stratifying an individual's risk beyond
Gail score alone.
BREVAGen was proven superior in determining breast cancer risk compared to Gail score alone.
BREVAGen reclassified 64% of Gail score intermediate risk subjects as either high or low risk for development of hormone-dependent breast cancer.
The patient's risk of breast cancer is calculated by combining their relative risk score from seven genetic markers, called SNPs (single nucleotide polymorphisms), with their
Gail score (factors that comprise the patient's clinical make-up including current age, age at menarche, age at live first birth, race/ethnicity, etc).
The patient's risk of breast cancer is calculated by combining their relative risk score from seven genetic markers, called SNP's (single nucleotide polymorphisms), with their
Gail score (factors that comprise the patient's clinical make-up including current age, age at menarche, age at live first birth, race/ethnicity, etc.
